Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 27555605

Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Pediatr Blood Cancer
Publication date
2017 Mar
First author
Kurmasheva RT

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Kurmasheva RT
      type
      Author
    2. name
      Sammons M
      type
      Author
    3. name
      Favours E
      type
      Author
    4. name
      Wu J
      type
      Author
    5. name
      Kurmashev D
      type
      Author
    6. name
      Cosmopoulos K
      type
      Author
    7. name
      Keilhack H
      type
      Author
    8. name
      Klaus CR
      type
      Author
    9. name
      Houghton PJ
      type
      Author
    10. name
      Smith MA
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Kurmasheva RT
      type
      Author
    2. name
      Sammons M
      type
      Author
    3. name
      Favours E
      type
      Author
    4. name
      Wu J
      type
      Author
    5. name
      Kurmashev D
      type
      Author
    6. name
      Cosmopoulos K
      type
      Author
    7. name
      Keilhack H
      type
      Author
    8. name
      Klaus CR
      type
      Author
    9. name
      Houghton PJ
      type
      Author
    10. name
      Smith MA
      type
      Author
    bibliography ids
    1. nci-bib-ad7944a5c1ce91ec482de7a1
    book metadata
    content sha256
    86ea6e490f69e40920f439e32718eea0475f6dd412d21b166e1c27676cc8dc96
    document type
    citation
    dois
    1. 10.1002/pbc.26218
    electronic publication date
    display
    2016 Aug 24
    precision
    day
    year
    2016
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:27555605
    immutable id
    pubmed:27555605@86ea6e490f69e40920f439e32718eea0475f6dd412d21b166e1c27676cc8dc96
    journal
    abbreviation
    Pediatr Blood Cancer
    issn electronic
    1545-5017
    issn print
    1545-5009
    issue
    3
    name
    Pediatric blood & cancer
    nlm unique id
    101186624
    pages
    Source null
    volume
    64
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      27555605
      provenance
      batch id
      d649bcb2d98dbbacd53c
      provider
      NCBI PubMed ESummary
      record sha256
      f6281f190cde743b779a47f5ebc85b3cd89f906a60c7c1b58ecb540f212dd0c0
      response sha256
      26648a40f123f366675007f51cc29befd1f9a89273ca2da87c477c54d2d15d20
      retrieved at
      2026-09-09T23:47:20.761544+00:00
      publication date
      display
      2017 Mar
      precision
      month
      year
      2017
      publication types
      1. Journal Article
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/27555605/
      title
      Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.

      Preserved source evidence · Independent clinical review pending · Not medical advice